AdBio partners

AdBio Partners is a Paris-based venture capital firm specializing in the life sciences sector, with a primary focus on therapeutic innovations and medical technologies. The firm is dedicated to supporting early-stage companies, typically investing in businesses from seed to Series A rounds. Their strategic objective is to transform groundbreaking scientific discoveries into viable commercial products, addressing critical needs in healthcare.

The firm manages multiple funds, notably AdBio Partners Fund II, which successfully closed at €150 million (approximately $160 million USD) in 2022. This significant capital base is supported by prominent institutional investors, including Bpifrance, which manages the French National Seed Fund (Fonds National d'Amorçage). This backing underscores AdBio Partners' crucial role in fostering innovation within the French biotech ecosystem. The firm leverages its deep scientific expertise and extensive network to identify and nurture promising ventures within the highly specialized life sciences domain.

AdBio Partners' investment strategy involves providing initial capital ranging from €1 million to €5 million (approximately $1.07 million to $5.35 million USD) per company. They typically plan for follow-on investments, potentially bringing their total commitment per portfolio company up to €10 million. The firm aims to build a diversified portfolio of 15 to 20 companies with Fund II, actively participating in their strategic and operational development. Their approach is hands-on, providing not just capital but also strategic guidance, industry connections, and operational support to help their portfolio companies navigate the complex landscape of drug development and medical innovation.